Division of Gerontology, Faculty of Health Sciences, Istanbul University Cerrahpaşa, Istanbul, Turkey.
Ist-GETAM, Center of Gerontechnology, Istanbul University Cerrahpaşa, Istanbul, Turkey.
Lymphat Res Biol. 2020 Oct;18(5):439-447. doi: 10.1089/lrb.2019.0064. Epub 2020 Feb 19.
Platelet-rich plasma (PRP) is an autologous concentrated preparation of platelets characterized by lymphangiogenetic and tissue-repairing effects. Although PRP has been safely used in many different fields, there is no clinical study regarding the use of PRP in lymphedema treatment in humans. We assessed the clinical outcomes of PRP in patients with lower extremity lymphedema (LEL) in a randomized controlled trial. Patients with secondary LEL were randomly allocated to one of three groups consisting of treatment with PRP with complex decongestive physiotherapy (PRP+CDP group), low-level laser therapy with CDP (LLLT+CDP group), and only CDP (CDP group). Assessment of Lymphedema Quality of-Life Questionnaire (LYMQOL) for health-related quality of life, lower-extremity-circumference (LEC) for edema, tissue dielectric constant (TDC) for extremity volume, 6-minute walking test (6MWT) for functional capacity, and numeric rating scale (NRS) scoring for extremity fullness were evaluated both before and after treatment. Forty-five patients (68.8% female) with mean age 40.84 ± 15.81 years were included in the study. Significant differences in LYMQOL, LEC, NRS, and TDC values both before and after treatment were found in all groups; however, there were no statistically significant difference in values between the three groups. In the PRP+CDP group, LYMQOL values had a larger effect size than the other two groups. Significant differences in 6MWT values both before and after treatment were found in PRP+CDP and LLLT+CDP groups; however, there was no statistically significant difference in the CDP group. This is the first clinical study to evaluate the usage of PRP in patients with secondary LEL. PRP might be an additional treatment option of lymphedema management; however, more clinical trials in humans are needed to yield more evidence in the usage of PRP in patients with lymphedema.
富血小板血浆(PRP)是一种自体浓缩的血小板制剂,具有淋巴管生成和组织修复作用。尽管 PRP 已在许多不同领域安全使用,但在人类淋巴水肿治疗中使用 PRP 尚无临床研究。我们在一项随机对照试验中评估了 PRP 在下肢淋巴水肿(LEL)患者中的临床疗效。继发性 LEL 患者被随机分配到三个治疗组之一,分别为 PRP 联合复杂减压物理治疗(PRP+CDP 组)、低水平激光治疗联合 CDP(LLLT+CDP 组)和仅 CDP(CDP 组)。使用淋巴水肿生活质量问卷(LYMQOL)评估健康相关生活质量,使用下肢周径(LEC)评估水肿,使用组织介电常数(TDC)评估肢体体积,使用 6 分钟步行试验(6MWT)评估功能能力,使用数字评分量表(NRS)评估肢体饱满度,在治疗前后进行评估。本研究共纳入 45 例(68.8%为女性)平均年龄为 40.84±15.81 岁的患者。所有组治疗前后 LYMQOL、LEC、NRS 和 TDC 值均有显著差异,但三组之间无统计学差异。在 PRP+CDP 组,LYMQOL 值的效应量大于其他两组。PRP+CDP 和 LLLT+CDP 组治疗前后 6MWT 值均有显著差异,但 CDP 组无统计学差异。这是第一项评估 PRP 在继发性 LEL 患者中应用的临床研究。PRP 可能是淋巴水肿管理的另一种治疗选择,但需要更多的人体临床试验来提供更多关于 PRP 在淋巴水肿患者中应用的证据。